ProPharma Group, a leading provider of compliance services, continues to expand its global presence, now with more than 1,100 employees across United States, Canada, Europe, Japan, and Australia. "The addition of Southwood Research's deep scientific expertise emphasizes ProPharma Group's commitment to providing industry leading regulatory support to our clients. ProPharma Group's robust regulatory capabilities, bolstered by the recent additions of The Weinberg Group in the United States and now Southwood Research in the UK, represent a truly unique end - to end global regulatory practice," said Dawn Sherman, ProPharma Groups's CEO.
Southwood Research is a leading provider of pre-approval regulatory science services to the pharmaceutical and biotech industries. "We are thrilled about our future as a part of ProPharma Group. The combination expands our global reach, as well as our ability to provide end-to-end services for our clients within regulatory affairs," said Colin Wheeler, Southwood Research's Managing Director.
Andy Coghlan, Managing Partner at WKCF, commented "We are delighted to have advised Colin on this transaction and believe he has an ideal partner in ProPharma Group to continue the rapid growth of Southwood".
Colin Wheeler added "Andy Coghlan, Charlie Copp and the WKCF team managed the entire sale process from start to finish in an exemplary manner. From sourcing potential buyers, through the negotiation of terms and then overseeing the completion process, they were on point at all times. I wouldn't hesitate to recommend them to anyone considering selling their business".
WK Corporate Finance
T: 020 7243 3403